Role of p38 and JNK MAPK signaling pathways and tumor suppressor p53 on induction of apoptosis in response to Ad-eIF5A1 in A549 lung cancer cells
© Taylor et al.; licensee BioMed Central Ltd. 2013
Received: 14 January 2013
Accepted: 17 April 2013
Published: 2 May 2013
The eukaryotic translation initiation factor 5A1 (eIF5A1) is a highly conserved protein involved in many cellular processes including cell division, translation, apoptosis, and inflammation. Induction of apoptosis is the only function of eIF5A1 that is known to be independent of post-translational hypusine modification. In the present study, we investigated the involvement of mitogen- and stress-activated protein kinases during apoptosis of A549 lung cancer cells infected with adenovirus expressing eIF5A1 or a mutant of eIF5A1 that cannot be hypusinated (eIF5A1K50A).
Using adenoviral-mediated transfection of human A549 lung cancer cells to over-express eIF5A1 and eIF5A1K50A, the mechanism by which unhypusinated eIF5A1 induces apoptosis was investigated by Western blotting, flow cytometry, and use of MAPK and p53 inhibitors.
Phosphorylation of ERK, p38 MAPK, and JNK was observed in response to adenovirus-mediated over-expression of eIF5A1 or eIF5A1K50A, along with phosphorylation and stabilization of the p53 tumor suppressor protein. Synthetic inhibitors of p38 and JNK kinase activity, but not inhibitors of ERK1/2 or p53 activity, significantly inhibited apoptosis induced by Ad-eIF5A1. Importantly, normal lung cells were more resistant to apoptosis induced by eIF5A1 and eIF5A1K50A than A549 lung cancer cells.
Collectively these data indicate that p38 and JNK MAP kinase signaling are important for eIF5A1-induced cell death and that induction of apoptosis was not dependent on p53 activity.
KeywordseIF5A Apoptosis MAPK p53 Hypusine
Eukaryotic translation initiation factor 5A (eIF5A) is a highly conserved protein that is post-translationally modified on a conserved lysine residue by two enzymes, deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH), which transfer a butylamine group from spermidine to a conserved lysine residue to produce the amino acid, hypusine. Two isoforms of eIF5A sharing 84% homology exist in humans but appear to have distinct biological functions . EIF5A1 is ubiquitously expressed in all examined cell types and is highly expressed in proliferating cells while eIF5A2 has restricted expression  and has been proposed to be an oncogene [3–5].
Although the physiological role of eIF5A1 has not been fully elucidated, it has been found to function both as a translation elongation factor during protein synthesis  and as a cytoplasmic shuttling protein regulating mRNA transport [7, 8]. EIF5A1 has also been implicated in the regulation of cell proliferation , inflammation , and apoptosis [11–16]. The pro-apoptotic function of eIF5A1 appears to be the only activity of eIF5A1 that is independent of hypusine modification [13, 15, 16], and over-expression of eIF5A1 mutated at the hypusination site, lysine 50, induces apoptosis in a wide range of cancer cell types, including colon , cervical , and blood . As well, in vivo xenograft studies have demonstrated the anti-tumoral activity of eIF5A1 in animal models of lung cancer, melanoma , and multiple myeloma . Apoptosis induced by an accumulation of non-hypusine-modified eIF5A1 has been correlated with loss of mitochondrial membrane potential and activation of caspases [15, 17] as well as up-regulation of p53 [13, 14]. However, eIF5A1 also induces apoptosis in p53-negative cell lines [14, 15], suggesting activation of p53-independent apoptotic pathways. Suppression of eIF5A1 expression using RNA interference reduces activation of mitogen-activated protein kinases (MAPKs) [16, 17] and can protect cells from apoptosis induced by cytotoxic drugs and cytokines [12, 15, 17].
MAPKs are serine/threonine protein kinases that participate in intracellular signaling during proliferation, differentiation, cellular stress responses, and apoptosis . Activation of MAPKs, including extracelluar signal-regulated kinases 1 and 2 (ERK1/2), p38 MAPK, and the stress activated protein kinase (SAPK)/c-Jun NH2-terminal kinase (JNK), has been implicated in the activity of numerous chemotherapy and genotoxic drugs. MAPK can regulate apoptosis through specific phosphorylation of downstream mediators of apoptosis, including the tumor suppressor p53, thus linking cellular stress signaling and regulation of p53 activity. Phosphorylation of p53 can regulate p53 activity by altering protein stability, interaction with co-activators, and transcription of target genes  as part of the cellular response to stress.
Despite numerous studies documenting the anti-tumoral activity of eIF5A1 in a wide variety of cancer cell types, there is limited knowledge about the mechanisms by which eIF5A1 modulates apoptosis. In the present study, adenovirus-mediated over-expression of eIF5A1 or eIF5A1K50A were found to activate ERK, p38 MAPK, and JNK coincident with the induction of apoptosis and phosphorylation of p53 tumor suppressor in A549 lung cancer cells. Inhibitors of p38 and JNK attenuated apoptosis by eIF5A1, suggesting that activation of MAPK/SAPK pathways is an important feature of eIF5A1-induced cell death. Ad-eIF5A1 also induced MEK-dependent phosphorylation and accumulation of p53. However, activity of p53 was not required for eIF5A1-induced apoptosis, indicating that alternative pathways are involved. Normal lung fibroblasts were found to be less sensitive to eIF5A1-induced apoptosis than A549 cells, possibly due to higher B cell lymphoma-2 (Bcl-2) levels and reduced activation of p38 MAPK. Activation of MAPK signaling pathways and apoptotic cell death of A549 cells were correlated to an accumulation of unmodified eIF5A1, suggesting that eIF5A1 anti-tumoral activity is independent of hypusine modification.
Ad-eIF5A1 and Ad-eIF5AK50A induce activation of ERK kinase, p38 MAPK, and JNK
EIF5A1 and eIF5A1K50A over-expression both resulted in dose-dependent phosphorylation of ERK, p38 MAPK and JNK (Figure 1A-D) at sites associated with increased kinase activity. A clear dose-dependent increase in phosphorylation of p38 in response to increasing Ad-eIF5A1 expression was observed (Figure 1C). Although expression of phosphorylated ERK decreases at the highest Ad-eIF5A1 expression level, there is a trend towards increased expression of phosphorylated ERK with increasing viral dose (Figure 1D). Phosphorylation of p90RSK, a kinase that is phosphorylated and activated by ERK, was also observed in response to Ad-eIF5A1 and Ad-eIF5A1K50A, indicating increased ERK activity (Figure 1A-B). An increase in phosphorylated p38 and a decrease in phosphorylated JNK were observed when Ad-eIF5A1K50A-infected cells were treated with the MAPK kinase (MEK) inhibitor U1026, indicating that ERK negatively and positively regulates p38 and JNK, respectively, in A549 cells (Figure 1B). Phosphorylation at serine 63 of the transcription factor c-Jun, a component of the activating protein-1 (AP-1) transcriptional complex was observed in response to Ad-eIF5A1 infection (Additional file 1: Figure S1), which is consistent with activation of SAPK/JNK  in response to eIF5A1.
Ad-eIF5A1 induces MEK-dependent activation and phosphorylation of the p53 tumor suppressor protein
Inhibitors of p38 MAPK and JNK protect A549 cells from Ad-eIF5A1-induced apoptosis
Normal lung fibroblasts are resistant to Ad-eIF5A1-induced apoptosis
The development of cancer gene therapies requires agents that target pathways that maximize anti-cancer activity. EIF5A1 has been identified as a viable cancer target that can be adapted for use in gene therapy approaches since its over-expression has been demonstrated to induce apoptosis in a wide variety of cancer types [11, 13–16]. As well, suppression of hypusinated eIF5A1 using a small interfering RNA (siRNA) has been shown to inhibit activation of Nuclear Factor kappa B (NF-κB) and ERK MAPK in multiple myeloma cells  and to potentiate the pro-apoptotic activity of an eIF5AK50R expression plasmid. SNS01-T, a nanoparticle containing an eIF5AK50R expression plasmid and an eIF5A1 siRNA, is currently being evaluated in a clinical trial in patients with advanced multiple myeloma [http://www.clinicaltrials.gov; Identifier: NCT01435720].
Although the precise mechanism underlying the role of eIF5A1 in cell death is unknown, it can induce apoptosis in a p53-dependent  or independent manner [13, 14] and activate the intrinsic mitochondrial pathway of apoptosis . In this study, adenoviral-mediated over-expression of eIF5A1 or eIF5AK50A was found to induce apoptosis in A549 lung cancer cells. The similarity in cellular response to eIF5A1 and eIF5A1K50A over-expression can be attributed to the rate-limiting activity of DHS and DOHH [13, 28] available to modify the large amounts of newly translated eIF5A1 generated by the virus. Indeed, a disproportionate accumulation of unhypusinated relative to hypusinated eIF5A1 that correlated with the induction of apoptosis was observed in the present study following Ad-eIF5A1 infection of A549 cells. Another important observation is that apoptosis induced by Ad-eIF5A1 or Ad-eIF5A1K50A infection was not correlated to a reduction in hypusine-eIF5A levels, suggesting that the apoptotic response is not a result of depletion of the hypusinated form of the protein.
MAPK signaling pathways can induce either cell proliferation or cell death depending on the cell type and stimulus. Infection of A549 cells with Ad-eIF5A1 or Ad-eIF5A1K50A induced activation of ERK, p38, and JNK MAPKs. ERK can antagonize apoptosis by phosphorylating pro-apoptotic Bcl-2 proteins, e.g., Bim, and inhibiting their function [29, 30]. ERK can also promote apoptosis by binding and phosphorylating the tumor suppressor p53 on serine 15  and up-regulating pro-apoptotic Bcl-2 proteins such as Bax . The p38 and JNK MAPK pathways are activated by a variety of cell stressors, including ultraviolet light (UV), radiation, cytotoxic drugs, and cytokines such as tumor necrosis factor alpha and interleukin 1. Activation of these pathways is often correlated with stress-related apoptosis, and inhibition of p38 and JNK has been demonstrated to prevent apoptosis resulting from a wide variety of stressors, including UV , ceramide , and genotoxic stress . Inhibitors of p38 and JNK inhibited apoptosis of A549 cells in response to Ad-eIF5A1 in the present study, indicating that activation of these kinases contributes to cell death mediated by an accumulation of unmodified eIF5A1. A member of the AP-1 transcription factor family, c-Jun, has been implicated in both cell survival and apoptosis  depending on the tissue and stimulus. The transcriptional activity of c-Jun and its ability to either enhance or protect against apoptosis are largely regulated by JNK-mediated phosphorylation of its transactivation domain at serines 63 and 73 [37, 38]. P38 MAPK has also been reported to phosphorylate c-Jun at serine 63 in T lymphocytes . In accordance with an increase in JNK and p38 MAPK activity, phosphorylation of c-Jun at serine 63 was observed following Ad-eIF5A1 infection, suggesting that eIF5A1-induced apoptosis may involve the AP-1 transcription factor complex.
The p53 tumor suppressor protein is activated by a variety of cellular stressors including reactive oxygen species, DNA damage, hypoxia and oncogene stimulation, and assists in the cellular response to stress by regulating cell growth and apoptosis. Post-translational modifications, including phosphorylation, modify the activity of p53 by regulating protein stability and enhancing DNA binding and transcriptional activity. Phosphorylation of p53 at serine 15 contributes to stability of p53 by interfering with binding to the E3 ubiquitin ligase, Mdm2 , and is also critical for the transactivation activity of p53 by promoting its association with the p300 coactivator protein . Intracellular signaling resulting from DNA damage leads to phosphorylation of p53 at serines 15, 20 and 37 resulting in decreased association with Mdm2 , thereby enhancing stability and activity of the p53 protein . Phosphorylation of serine 15 is critical for p53-induced apoptosis  and has been associated with increased expression of p53-responsive pro-apoptotic genes . Oligomerization of p53, which is critical to its transcriptional activity, is regulated by phosphorylation at serine 392 . The involvement of ERK in the regulation of p53 stability and activity through direct phosphorylation has long been recognized . In the present study, eIF5A1 over-expression induced MEK-dependent accumulation and phosphorylation of the p53 tumor suppressor protein on serines 15, 37, and 392, as well as up-regulation of the p53-responsive genes, TNFR1 and p53. However, in spite of increased p53 activity in Ad-eIF5A1-infected cells, an inhibitor of p53 was not sufficient to inhibit eIF5A1-induced apoptosis. Thus, apoptosis of A549 lung cancer cells induced by eIF5A1 does not appear to be dependent on p53 activity, although increased expression/stability of p53 induced by eIF5A1 may lower the apoptotic threshold  and thereby contribute to the pro-apoptotic activity of eIF5A.
Increased expression of Bax and the BH3-only protein, Bid, was observed in response to Ad-eIF5A1 over-expression, both being pro-apoptotic proteins that are transcriptionally regulated by stress-activated p53 . Hypusine-modified eIF5A1 has been proposed to act as a tumor suppressor in Eμ-myc lymphomagenesis in mice, in part by promoting expression of Bax . However, in the present study, increased expression of both p53 and Bax was correlated with an accumulation of unmodified eIF5A, since hypusine-eIF5A1 levels were relatively unaffected by Ad-eIF5A1 infection. The pro-apoptotic BH3-only Bcl-2 family member, Bid, is cleaved by caspase 8 and then interacts with other pro-apoptotic Bcl-2 family members, specifically Bax and Bak, to connect activation of the death receptor pathway to the internal mitochondrial apoptosis pathway. In contrast to what is observed in the event of death receptor-mediated apoptosis, cleavage of Bid to tBid was not apparent during eIF5A1-induced apoptosis, although increased expression of full length Bid was observed. Although tBid is the form of Bid typically associated with the induction of apoptosis, full-length Bid has been found to associate with the mitochondrial membrane and promote apoptosis in hippocampal neurons . While tBid is typically observed in the late stages of apoptosis , full-length Bid has been reported to regulate the activation of Bax during apoptosis by facilitating its oligomerization and insertion into the mitochondrial membrane .
Malignant cells often display increased sensitivity to chemotherapy drugs and radiation. Although the molecular pathways involved in this increased sensitivity have not been completely elucidated, the sensitization of oncogenically-transformed cells to cytotoxic stresses has been attributed to the potentiation of JNK and p38 MAPK activation . In this study, WI-38 normal lung cells were found to be more resistant than transformed A549 cells to eIF5A1-induced apoptosis. Infection with adenovirus expressing eIF5A1 or eIF5A1K50A caused an induction of p38 and ERK MAPK phosphorylation in A549 cells, but had a more modest effect on p38 phosphorylation in WI-38 cells, suggesting that potentiation of p38 MAPK activation may have contributed to the increased sensitivity of A549 cells to Ad-eIF5A1 infection.
In summary, this study has identified the activation of MAPKs as an important step in the signaling cascade that leads to the induction of p53-independent apoptotic cell death in response to over-expression of unhypusinated eIF5A1 in A549 lung carcinoma cells. The importance of p38 and JNK activation during eIF5A1-induced apoptosis is highlighted by the ability of inhibitors of these MAPKs to inhibit apoptosis ensuing from Ad-eIF5A1 infection. Furthermore, malignant A549 cells demonstrated enhanced sensitivity to eIF5A1-induced apoptosis compared to normal lung cells, suggesting that eIF5A1-based therapy may spare normal tissues. This work emphasizes the potential of therapeutic application of eIF5A1 in the treatment in cancers.
Material and methods
Chemicals and reagents
The DHS inhibitor, N1-guanyl-1,7-diaminoheptane (GC7) was purchased from Biosearch Technologies and used at a concentration of 50 μM. The MEK inhibitor U1026, the p38 inhibitor SB203580, the JNK inhibitor SP600125, and the p53 inhibitor pifithrin-α were obtained from Calbiochem. The FITC Annexin V Apoptosis Detection Kit II was obtained from BD Pharmingen. BD Transduction Laboratories and Calbiochem supplied the eIF5A and β-actin antibodies, respectively. All other primary antibodies were purchased from Cell Signaling Technology. Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Sigma-Aldrich. PCR primers were obtained from Sigma-Aldrich and iQ SYBR Green Supermix was obtained from Bio-Rad.
Cell culture, drug treatment, and infection with adenovirus
A549 human lung adenocarcinoma cells and WI-38 human normal lung fibroblast cells were obtained from the American Type Culture Collection. Both cell lines were maintained in RPMI 1640 supplemented with 1 mM sodium pyruvate and 10% fetal bovine serum (FBS). Adenoviral vectors (Adenovirus 5 serotype, E1 and E3-deleted) expressing β-galactosidase (LacZ), eIF5A1, and eIF5A1K50A were constructed and propagated as described (13). For adenovirus-mediated transfection, cells were seeded at 100,000 cells per well on a 24-well tissue culture plate and incubated with adenovirus constructs at multiplicities of infection (MOI), the ratio of the number of infectious viral particles to the number of target cells, ranging from 5 to 80 in medium containing 0.5% FBS. Four hours later, the media was replaced with growth media or growth media containing 10 μM of the inhibitors U1026, SB203580, SP600125, or 30 μM of pifithrin. Dimethylsulfoxide (DMSO) was included as a vehicle control.
SDS-PAGE and western blotting
Cell lysate was prepared in lysis buffer [62.5 mM Tris–HCl (pH 7.2), 2% SDS, 10% glycerol, protease inhibitors] followed by brief sonication. Protein concentration was quantified using the Bicinchoninic Acid Kit (Sigma-Aldrich). One to ten micrograms of protein was separated by SDS-PAGE and western blot analysis was performed by incubating with primary antibodies for either one hour (eIF5A, β-actin) or overnight at 4°C (all other antibodies). After incubation with HRP-conjugated secondary antibodies, the antibody-protein complexes were visualized using enhanced chemiluminescence (GE Health). Densitometry analysis was performed using TotalLab TL100 vs2006 software. In order to distinguish between the different post-translational modification states of eIF5A, two-dimensional gel electrophoresis followed by western blot analysis using eIF5A antibody was performed as described . Briefly, cell lysates were harvested in cold lysis buffer (7 M Urea, 2 M Thiourea, 30 mM Tris, 4% CHAPS, 1 × protease inhibitor cocktail), loaded on Immobiline™ Drystrips (GE Healthcare, pH 4–7, 7 cm) followed by electrofocusing with Ethan™ IPGphor II™ using the following program: 500 V 0.5 hr, Grad 1000 V 0.5 hr, Grad 5000 V 1.5 h, 5000 V 6 hr, 500 V 5 hr. Proteins were then fractionated on a 12% SDS-PAGE gel, transferred to a PVDF membrane, and eIF5A post-translational modified forms were identified by blotting with an antibody against eIF5A1.
Total RNA was isolated from cells infected with adenoviral constructs using the GenElute™ Mammalian Total RNA Miniprep Kit (Sigma-Aldrich). Reverse transcription was performed on 1.2 micrograms of total RNA using AMV reverse transcriptase (Roche Applied Science) according to the manufacturer’s instructions. PCR reactions contained 500 nM of each primer, 1× of iQ SYBR Green Supermix (Bio-Rad), and 1 μL of cDNA. Real time PCR was performed in a MiniOpticon Real Time PCR Detection System (Bio-Rad) for 40 cycles using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a reference gene. The tumor suppressor p53 was amplified using the following primers : forward 5′-CGCTGCTCAGATAGCGATGGTC-3′; reverse 5′-CTTCTTTGGCTGGGGAGAGGAG-3′. The primers used to amplify tumor necrosis factor receptor 1 (TNFR1) were the following: forward 5′-ATCTCTTCTTGCACAGTGG-3′; reverse 5′-CAATGGAGTAGAGCTTGGAC-3′. The primers used to amplify the housekeeping gene GAPDH were: forward 5′-CTGTAGCCCCCATGTTCGTCAT-3′; and reverse 5′ –CCACCACCCTGTTGCTGTAG-3′.
Apoptosis was quantified by labeling cells with Annexin V-FITC and propidium iodide using the FITC Annexin V Apoptosis Detection Kit II, according to the manufacturer’s instructions, followed by analysis on a BD FACSVantage SE system (BD Bioscience) with an argon laser source. A minimum of five thousand cells was counted and the data was analyzed using WinMDI 2.8 software.
Student’s t-test was used for statistical analysis. Significance was determined by a confidence level above 95% (P < 0.05).
B cell lymphoma-2
Eukaryotic translation initiation factor 5A1
Extracellular signal-regulated kinase
Fetal bovine serum
Glyceraldehyde 3-phosphate dehydrogenase
c-Jun NH2-terminal kinase
Mitogen-activated protein kinases
Multiplicities of infection
Nuclear Factor Kappa B
Quantitative reverse transcription polymerase chain reaction
Small interfering RNA
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
Stress activated protein kinase
Tumor necrosis factor receptor 1
We thank Dr. Sarah Francis for her thorough review of the manuscript.
- Caraglia M, Park MH, Wolff EC, Marra M, Abbruzzese A: eIF5A isoforms and cancer: two brothers for two functions?. Amino Acids. 2013, 44: 103-109. 10.1007/s00726-011-1182-x.PubMed CentralView ArticlePubMedGoogle Scholar
- Jenkins ZA, Hååg PG, Johansson HE: Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics. 2001, 71: 101-109. 10.1006/geno.2000.6418.View ArticlePubMedGoogle Scholar
- Guan XY, Fung JM, Ma NF, Lau SH, Tai LS, Xie D, Zhang Y, Hu L, Fang Y, Sham JS: Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res. 2004, 64: 4197-4200. 10.1158/0008-5472.CAN-03-3747.View ArticlePubMedGoogle Scholar
- Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, Lau SH, Li Y, Li Y, Guan XY: Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology. 2010, 51: 1255-1263. 10.1002/hep.23451.View ArticlePubMedGoogle Scholar
- Xie D, Ma NF, Pan ZZ, Wu HX, Liu YD, Wu GQ, Kung HF, Guan XY: Overexpression of EIF-5A2 is associated with metastasis of human colorectal carcinoma. Hum Pathol. 2008, 39: 80-86. 10.1016/j.humpath.2007.05.011.View ArticlePubMedGoogle Scholar
- Saini P, Eyler DE, Green R, Dever TE: Hypusine-containing protein eIF5A promotes translation elongation. Nature. 2009, 459: 118-121. 10.1038/nature08034.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu YP, Nemeroff M, Yan YP, Chen KY: Interaction of eukaryotic initiation factor 5A with the human immunodeficiency virus type 1 Rev response element RNA and U6 snRNA requires deoxyhypusine or hypusine modification. Biol Signals. 1997, 6: 166-174. 10.1159/000109123.View ArticlePubMedGoogle Scholar
- Maier B, Ogihara T, Trace AP, Tersey SA, Robbins RD, Chakrabarti SK, Nunemaker CS, Stull ND, Taylor CA, Thompson JE, Dondero RS, Lewis EC, Dinarello CA, Nadler JL, Mirmira RG: The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice. J Clin Invest. 2010, 120: 2156-2170. 10.1172/JCI38924.PubMed CentralView ArticlePubMedGoogle Scholar
- Park MH, Wolff EC, Folk JE: Hypusine: its post-translational formation in eukaryotic initiation factor 5A and its potential role in cellular regulation. Biofactors. 1993, 4: 95-104.PubMedGoogle Scholar
- Moore CC, Martin EN, Lee G, Taylor C, Dondero R, Reznikov LL, Dinarello C, Thompson J, Scheld WM: Eukaryotic translation initiation factor 5A small interference RNA-liposome complexes reduce inflammation and increase survival in murine models of severe sepsis and acute lung injury. J Infect Dis. 2008, 198: 1407-1414. 10.1086/592222.PubMed CentralView ArticlePubMedGoogle Scholar
- Li A, Li HY, Jin BF, Ye QN, Zhou T, Yu XD, Pan X, Man JH, He K, Yu M, Hu MR, Wang J, Yang SC, Shen BF, Zhang XM: A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem. 2004, 279: 49251-49258. 10.1074/jbc.M407165200.View ArticlePubMedGoogle Scholar
- Taylor CA, Senchyna M, Flanagan J, Joyce EM, Cliche DO, Boone AN, Culp-Stewart S, Thompson JE: Role of eIF5A in TNF-alpha-mediated apoptosis of lamina cribrosa cells. Invest Ophthalmol Vis Sci. 2004, 45: 3568-3576. 10.1167/iovs.03-1367.View ArticlePubMedGoogle Scholar
- Taylor CA, Sun Z, Cliche DO, Ming H, Eshaque B, Jin S, Hopkins MT, Thai B, Thompson JE: Eukaryotic translation initiation factor 5A induces apoptosis in colon cancer cells and associates with the nucleus in response to tumour necrosis factor alpha signalling. Exp Cell Res. 2007, 313: 437-449. 10.1016/j.yexcr.2006.09.030.View ArticlePubMedGoogle Scholar
- Jin S, Taylor CA, Liu Z, Sun Z, Ye B, Thompson JE: Suppression of primary and disseminated murine tumor growth with eIF5A1 gene therapy. Gene Ther Mol Biol. 2008, 12: 207-218.Google Scholar
- Sun Z, Cheng Z, Taylor CA, McConkey BJ, Thompson JE: Apoptosis induction by eIF5A1 involves activation of the intrinsic mitochondrial pathway. J Cell Physiol. 2010, 223: 798-809.PubMedGoogle Scholar
- Taylor CA, Liu Z, Tang TC, Zheng Q, Francis S, Wang TW, Ye B, Lust JA, Dondero R, Thompson JE: Modulation of eIF5A expression using SNS01 nanoparticles inhibits NF-κB activity and tumor growth in murine models of multiple myeloma. Mol Ther. 2012, 20: 1305-1314. 10.1038/mt.2012.94.PubMed CentralView ArticlePubMedGoogle Scholar
- Tan X, Wang DB, Lu X, Wei H, Zhu R, Zhu SS, Jiang H, Yang ZJ: Doxorubicin induces apoptosis in H9c2 cardiomyocytes: role of overexpressed eukaryotic translation initiation factor 5A. Biol Pharm Bull. 2010, 33: 1666-1672. 10.1248/bpb.33.1666.View ArticlePubMedGoogle Scholar
- Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature. 2001, 410: 37-40. 10.1038/35065000.View ArticlePubMedGoogle Scholar
- Appella E, Anderson CW: Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem. 2001, 268: 2764-2772. 10.1046/j.1432-1327.2001.02225.x.View ArticlePubMedGoogle Scholar
- Ip Y, Davis RJ: Signal transduction by the c-Jun N-terminal kinase (JNK) – from inflammation to development. Curr Opin Cell Biol. 1998, 10: 205-219. 10.1016/S0955-0674(98)80143-9.View ArticlePubMedGoogle Scholar
- Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q, Wu M, Otterson GA, Zhu WG: Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol. 2006, 26: 2782-2790. 10.1128/MCB.26.7.2782-2790.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Shieh SY, Ikeda M, Taya Y, Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997, 91: 325-334. 10.1016/S0092-8674(00)80416-X.View ArticlePubMedGoogle Scholar
- Dumaz N, Meek DW: Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 1999, 18: 7002-7010. 10.1093/emboj/18.24.7002.PubMed CentralView ArticlePubMedGoogle Scholar
- Sanchez-Prieto R, Rojas JM, Taya Y, Gutkind JS: A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res. 2000, 60: 2464-2472.PubMedGoogle Scholar
- She QB, Chen N, Dong Z: ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem. 2000, 275: 20444-20449. 10.1074/jbc.M001020200.View ArticlePubMedGoogle Scholar
- Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995, 80: 293-299. 10.1016/0092-8674(95)90412-3.View ArticlePubMedGoogle Scholar
- Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS: BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol. 2002, 4: 842-849. 10.1038/ncb866.View ArticlePubMedGoogle Scholar
- Clement PM, Johansson HE, Wolff EC, Park MH: Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J. 2006, 273: 1102-1114. 10.1111/j.1742-4658.2006.05135.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K, Cook SJ: Extracellular signal regulated kinases 1/2 are serum-stimulated “Bim(EL) kinases” that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem. 2004, 279: 8837-8847. 10.1074/jbc.M311578200.View ArticlePubMedGoogle Scholar
- Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, Degenhardt K, White E, Cook SJ: ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J. 2007, 26: 2856-2867. 10.1038/sj.emboj.7601723.PubMed CentralView ArticlePubMedGoogle Scholar
- Persons DL, Yazlovitskaya EM, Pelling JC: Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem. 2000, 275: 35778-35785. 10.1074/jbc.M004267200.View ArticlePubMedGoogle Scholar
- Kim YK, Kim HJ, Kwon CH, Kim JH, Woo JS, Jung JS, Kim JM: Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol. 2005, 25: 374-382. 10.1002/jat.1081.View ArticlePubMedGoogle Scholar
- Butterfield L, Storey B, Maas L, Heasley LE: c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. J Biol Chem. 1997, 272: 10110-10116. 10.1074/jbc.272.15.10110.View ArticlePubMedGoogle Scholar
- Brenner B, Koppenhoefer U, Weinstock C, Linderkamp O, Lang F, Gulbins E: Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem. 1997, 272: 22173-22181. 10.1074/jbc.272.35.22173.View ArticlePubMedGoogle Scholar
- Chen Z, Seimiya H, Naito M, Mashima T, Kizaki A, Dan S, Imaizumi M, Ichijo H, Miyazono K, Tsuruo T: ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene. 1999, 18: 173-180. 10.1038/sj.onc.1202276.View ArticlePubMedGoogle Scholar
- Behrens A, Sibilia M, Wagner EF: Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet. 1999, 21: 326-329. 10.1038/6854.View ArticlePubMedGoogle Scholar
- Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR: Phosphorylation of c-jun mediated by MAP kinases. Nature. 1991, 353: 670-674. 10.1038/353670a0.View ArticlePubMedGoogle Scholar
- Morton S, Davis RJ, McLaren A, Cohen P: A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J. 2003, 22: 3876-3886. 10.1093/emboj/cdg388.PubMed CentralView ArticlePubMedGoogle Scholar
- Humar M, Loop T, Schmidt R, Hoetzel A, Roesslein M, Andriopoulos N, Pahl HL, Geiger KK, Pannen BH: The mitogen-activated protein kinase p38 regulates activator protein 1 by direct phosphorylation of c-Jun. Int J Biochem Cell Biol. 2007, 39: 2278-2288. 10.1016/j.biocel.2007.06.013.View ArticlePubMedGoogle Scholar
- Bean LJ, Stark GR: Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV. Oncogene. 2001, 20: 1076-1084. 10.1038/sj.onc.1204204.View ArticlePubMedGoogle Scholar
- Unger T, Sionov RV, Moallem E, Yee CL, Howley PM, Oren M, Haupt Y: Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene. 1999, 18: 3205-3212. 10.1038/sj.onc.1202656.View ArticlePubMedGoogle Scholar
- Amano T, Nakamizo A, Mishra SK, Gumin J, Shinojima N, Sawaya R, Lang FF: Simultaneous phosphorylation of p53 at serine 15 and 20 induces apoptosis in human glioma cells by increasing expression of pro-apoptotic genes. J Neurooncol. 2009, 92: 357-371. 10.1007/s11060-009-9844-1.View ArticlePubMedGoogle Scholar
- Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella ED: Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry. 1997, 36: 10117-10124. 10.1021/bi970759w.View ArticlePubMedGoogle Scholar
- Wu GS: The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther. 2004, 3: 156-161.View ArticlePubMedGoogle Scholar
- Sax JK, El-Deiry WS: p53 downstream targets and chemosensitivity. Cell Death Differ. 2003, 10: 413-417. 10.1038/sj.cdd.4401227.View ArticlePubMedGoogle Scholar
- Scuoppo C, Miething C, Lindqvist L, Reyes J, Ruse C, Appelmann I, Yoon S, Krasnitz A, Teruya-Feldstein J, Pappin D, Pelletier J, Lowe SW: A tumour suppressor network relying on the polyamine-hypusine axis. Nature. 2012, 487: 244-248. 10.1038/nature11126.PubMed CentralView ArticlePubMedGoogle Scholar
- König HG, Rehm M, Gudorf D, Krajewski S, Gross A, Ward MW, Prehn JH: Full length Bid is sufficient to induce apoptosis of cultured rat hippocampal neurons. BMC Cell Biol. 2007, 8: 7-10.1186/1471-2121-8-7.PubMed CentralView ArticlePubMedGoogle Scholar
- Pei Y, Xing D, Gao X, Liu L, Chen T: Real-time monitoring full length bid interacting with Bax during TNF-alpha-induced apoptosis. Apoptosis. 2007, 12: 1681-1690. 10.1007/s10495-007-0091-7.View ArticlePubMedGoogle Scholar
- Eskes R, Desagher S, Antonsson B, Martinou JC: Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol. 2000, 20: 929-935. 10.1128/MCB.20.3.929-935.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Benhar M, Dalyot I, Engelberg D, Levitzki A: Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol. 2001, 21: 6913-6926. 10.1128/MCB.21.20.6913-6926.2001.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.